Article

More private payers to cover tibial nerve stimulation

Uroplasty, Inc. (Minneapolis) has announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.

Uroplasty, Inc. (Minneapolis) has announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.

Effective Aug. 1, 2011, Health Care Service Corp. will begin covering and paying for PTNS therapy for patients in Texas, Illinois, New Mexico, and Oklahoma. Additionally, effective May 18, 2011, BlueCross BlueShield of Nebraska initiated coverage of PTNS treatments.

"We have now secured coverage from three of the four largest private payers in the United States," said David Kaysen, president and CEO of Uroplasty. "We estimate that in total, the Medicare and private-pay carriers that today provide coverage for PTNS treatments represent approximately 115 million lives."

Related Videos
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Behavioral intervention may improve psychological distress after testicular cancer
November 25th 2024

Behavioral intervention may improve psychological distress after testicular cancer

Hannah Clarke
The study showed significant reductions in both anxiety and depressive symptoms following the intervention.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Enrollment goal met in phase 3 SOLAR-RECUR trial
November 22nd 2024

Enrollment goal met in phase 3 SOLAR-RECUR trial

Hannah Clarke
The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
FDA accepts sNDA for darolutamide plus ADT in mHSPC
November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke
The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.
Study indicates overtreatment of men with prostate cancer and limited life expectancy
November 20th 2024

Study indicates overtreatment of men with prostate cancer and limited life expectancy

Hannah Clarke
“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment," says Timothy J. Daskivich, MD.
© 2024 MJH Life Sciences

All rights reserved.